Market Research Reports

Peptide Therapeutics Market (by Synthesis - SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, CNS & others, by Types - Innovative & Generic and by Delivery) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

128pages
Published Date: 2013-03-13
 

Description



Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body. 

Likewise, peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses.

This report analyzes the peptide therapeutics market by types of applications (cancer, metabolic, neurological diseases and others), route of administration, by types (innovative and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and technology. Each of these markets is analyzed by studying the current and future market scenario, with estimation for the period 2010 – 2018 in terms of value in USD million.

The peptide therapeutics market is also segmented based on geography into North America, Europe, Asia and rest of the world (RoW) regions. The market for all these geographical regions is provided in the report in terms of revenue. The report provides complete analysis of the factors responsible for driving and restraining the global peptide therapeutics market. 

Competitive landscape is provided with market players profiled with attributes like company overview, financial overview, business strategies, product portfolio and recent developments. Market shares in 2011 for the key players and CMO players are provided and recommendations to accentuate market shares and ensure sustainability are provided in this report

Key market players profiled in this report are Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsen and others. While CMOs major players profiled are Bachem, Lonza, Peptisyntha, Polypeptide group and others.

Peptide Therapeutics Market, by Applications
  • Cancer
  • Metabolic
  • Cardiovascular
  • Dermatology
  • Anti-Infection
  • Neurology
  • Gastro Intestinal
  • Renal 
  • Respiratory
  • Pain
  • Others
Peptide Therapeutics Market, by Route of Administration
  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal
  • Others
Peptide Therapeutics Market, by Types
  • Innovative
  • Generics
Peptide Therapeutics Market, by API Peptide 
  • In-House
  • CMO (Contract Manufacturing Organization)
Peptide Therapeutics by Technology
  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid 
Peptide Therapeutics Market, by Geography
  • North America
  • Europe
  • Asia
  • RoW

Table of Contents


Table of content

Chapter 1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)
      2.1.1 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
      2.1.2 Global API peptide therapeutics market, 2011 (USD Million)
      2.1.3 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)

Chapter 3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
      3.2.1 Increase in cancer patient population to propel the growth of new peptides
      3.2.2 Rise in metabolic disorders to escalate the growth of peptides market
      3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years
                3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011
      3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides
3.3 Restraints & challenges
      3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers
      3.3.2 Lack of regulatory standards hampering the growth of the market
      3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers
3.4 Opportunities
      3.4.1 Rise in cancer vaccine to drive the future market
      3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
      3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth
              3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants
              3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)
3.5 Porters five forces analysis
      3.5.1 Porter’s five forces analysis of global peptide therapeutics market
      3.5.2 Bargaining power of suppliers
      3.5.3 Bargaining power of buyers
      3.5.4 Threat of new entrants
      3.5.5 Threat of substitutes
      3.5.6 Competitive rivalry
3.6 Market attractiveness analysis
      3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications
4.1 Introduction
      4.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million)
      4.1.2 Cancer
              4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
      4.1.3 Metabolic
              4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
               4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
      4.1.4 Cardiovascular
              4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million)
      4.1.5 Dermatology
              4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)
      4.1.6 Anti-Infection
              4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012
              4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)
     4.1.7 Neurology
              4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)
     4.1.8 Gastro Intestinal
              4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
     4.1.9 Renal
              4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)
   4.1.10 Respiratory
              4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)
   4.1.11 Pain
              4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)
    4.1.12 Others
              4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012
              4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
      5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million)
      5.1.2 Methods of delivery for peptide drugs
5.2 Parenteral Route
      5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million)
5.3 Oral Route
      5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million)
5.4 Pulmonary Route
      5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million)
5.5 Mucosal Route
      5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million)
5.6 Others (Intradermal & Nasal)
      5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million)

Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments
6.1 Introduction
      6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)
6.2 Peptide Therapeutics – Innovative market
      6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market
      6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics – In-house market
      7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO)
      7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)

Chapter 8 Peptide Therapeutics Market, By Technology
8.1 Introduction
      8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million)
8.2 Solid Phase Peptide Synthesis (SPPS)
      8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
      8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million)
8.4 Hybrid Technology
      8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)

Chapter 9 Peptide Therapeutics Market, By Geography
9.1 Introduction
      9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018
9.2 North America
      9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.3 Europe
      9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia 
      9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)
9.5 Rest of World
      9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
      10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)
10.3 Market share by key players in CMO segment
      10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)

Chapter 11 Recommendations
11.1 Success strategies
      11.1.1 Rigorous research and development (R&D) initiatives
      11.1.2 Investing in emerging economies
      11.1.3 Investing in recent technologies such as HPPS TEchnology
      11.1.4 Mergers and acquisitions
11.2 Barriers to be considered
      11.2.1 The high cost of peptide synthesis
      11.2.2 Weak pipeline peptide drug candidates in phase III

Chapter 12 Company Profiles
12.1 Bachem Holding AG
      12.1.1 Company overview
      12.1.2 Financial overview
      12.1.3 Strategic overview
                12.1.3.1 Collaborations
                12.1.3.2 Expansion
                12.1.3.3 Divestiture
                12.1.3.4 Recent developments
12.2 Eli Lilly and Company
      12.2.1 Company overview
      12.2.2 Financial overview
      12.2.3 Strategic overview
                12.2.3.1 Agreements
                12.2.3.2 Approvals
      12.2.4 Recent developments
12.3 Pfizer, Inc.
      12.3.1 Company overview
      12.3.2 Financial overview
      12.3.3 Strategic overview
                12.3.3.1 Mergers and acquisitions
                12.3.3.2 Divestiture
                12.3.3.3 Approvals
      12.3.4 Recent developments
12.4 Amgen, Inc.
      12.4.1 Company overview
      12.4.2 Financial overview
      12.4.3 Strategic overview
                12.4.3.1 Mergers and acquisitions
                12.4.3.2 Licensing
      12.4.4 Recent developments
12.5 Takeda Pharmaceutical Company Limited
      12.5.1 Company overview
      12.5.2 Financial overview
      12.5.3 Strategic overview
                12.5.3.1 Partnerships and collaborations
                12.5.3.2 Mergers and acquisitions
      12.5.4 Recent developments
12.6 Teva Pharmaceuticals
      12.6.1 Company overview
      12.6.2 Financial overview
      12.6.3 Strategic overview
                12.6.3.1 Mergers and acquisitions
                12.6.3.2 Investing in generic and biosimilar segments
      12.6.4 Recent developments
12.7 Lonza Inc.
      12.7.1 Company overview
      12.7.2 Financial overview
      12.7.3 Strategic overview
                12.7.3.1 Investing in emerging economies
                12.7.3.2 Mergers and acquisitions
      12.7.4 Recent developments
12.8 Peptisyntha
      12.8.1 Company overview
      12.8.2 Financial overview
      12.8.3 Strategic overview
                12.8.3.1 Arranging and participating in trade shows
                12.8.3.2 Continuous manufacturing expansion
12.9 Sanofi
      12.9.1 Company overview
      12.9.2 Financial overview
      12.9.3 Strategic overview
                12.9.3.1 Acquisitions
                12.9.3.2 Divestments
      12.9.4 Recent developments
12.10 Ipsen
      12.10.1 Company overview
      12.10.2 Financial overview
      12.10.3 Strategic overview
                  12.10.3.1 Large investment in research and development
                  12.10.3.2 Global expansion through partnership
      12.10.4 Recent developments
12.11 PolyPeptide Group.
      12.11.1 Company overview
      12.11.2 Strategic overview
                  12.11.2.1 Focus on product portfolio extension and quality product development
                  12.11.2.2 Global expansion through merger and acquisition
12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)
      12.12.1 Company overview
      12.12.2 Amylin Pharmaceuticals LLC
      12.12.3 Financial overview
      12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)
                  12.12.4.1 Entering into strategic collaborations
                  12.12.4.2 Corporate social responsibility
                  12.12.4.3 Rigorous R&D initiatives
      12.12.5 Recent developments
12.13 AstraZeneca PLC
      12.13.1 Company overview
      12.13.2 Financial overview
      12.13.3 Strategic overview
                  12.13.3.1 Rigorous R&D initiatives
                  12.13.3.2 Investing in emerging economies
      12.13.4 Recent developments
12.14 Roche
      12.14.1 Company overview
      12.14.2 Financial overview
      12.14.3 Strategic overview
                  12.14.3.1 Research and development initiatives
                  12.14.3.2 Focus on personalized healthcare
                  12.14.3.3 Focus on new and emerging markets
                  12.14.3.4 Funding awareness programs
      12.14.4 Recent developments
12.15 GlaxoSmithKline (GSK)
      12.15.1 Company overview
      12.15.2 Financial overview
      12.15.3 Strategic overview
                  12.15.3.1 Research and development initiatives
                  12.15.3.2 Direct to Consumer Advertising
                  12.15.3.3 Mergers and acquisitions
12.15.4 Recent developments
12.16 Merck & Co.
      12.16.1 Company overview
      12.16.2 Financial overview
      12.16.3 Strategic overview
                  12.16.3.1 Corporate social responsibility
                  12.16.3.2 R&D Initiatives
                  12.16.3.3 Strategic alliances and out-licensing
12.16.4 Recent developments
12.17 Novartis AG
      12.17.1 Company overview
      12.17.2 Financial overview
      12.17.3 Strategic overview
                  12.17.3.1 Mergers and acquisitions
                  12.17.3.2 Memorandum of understanding
      12.17.4 Recent developments
12.18 Novo-Nordisk A/S
      12.18.1 Company overview
      12.18.2 Financial overview
      12.18.3 Strategic overview
                  12.18.3.1 Partnerships and alliances
      12.18.4 Agreements
      12.18.5 Recent developments

List of Figures

FIG. 1 Global Peptide Therapeutics: Market Snapshot 18
FIG. 2 Global peptide therapeutics market, by revenue, 2010 – 2018 (USD Million) 23
FIG. 3 Global API peptide therapeutics market, 2011 (USD Million) 24
FIG. 4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%) 25
FIG. 5 Global peptide therapeutics trials growth, 1970 - 2011 27
FIG. 6 Porter’s five forces analysis for global peptide therapeutics market 32
FIG. 7 Market attractiveness analysis of the global peptide therapeutics market, by geography 34
FIG. 8 Global Cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 38
FIG. 9 Global cancer peptide therapeutics market revenues, 2010 - 2018 (USD Million) 39
FIG. 10 Global metabolic peptide therapeutics pipeline drugs analysis , number of trials, 2009 - 2012 40
FIG. 11 Global metabolic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 40
FIG. 12 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 41
FIG. 13 Global cardiovascular peptide therapeutics market revenues, 2010 - 2018 (USD Million) 42
FIG. 14 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 43
FIG. 15 Global dermatology peptides market revenues, 2010 - 2018 (USD Million) 44
FIG. 16 Global anti-infection pipeline drugs analysis, number of trials, 2009 - 2012 45
FIG. 17 Global anti-infection peptides market revenues, 2010 - 2018 (USD Million) 46
FIG. 18 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 47
FIG. 19 Global neurology peptides market revenues, 2010 - 2018 (USD Million) 47
FIG. 20 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 48
FIG. 21 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million) 49
FIG. 22 Global renal pipeline drugs analysis, number of trials, 2009 - 2012 50
FIG. 23 Global renal peptides market revenues, 2010 - 2018 (USD Million) 50
FIG. 24 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 51
FIG. 25 Global respiratory peptides market, revenues, 2010 - 2018 (USD Million) 52
FIG. 26 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 53
FIG. 27 Global pain peptides market revenues, 2010 - 2018 (USD Million) 53
FIG. 28 Global others pipeline drugs analysis, number of trials, 2009 - 2012 54
FIG. 29 Global others peptides market revenues, 2010 - 2018 (USD Million) 55
FIG. 30 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 58
FIG. 31 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million) 59
FIG. 32 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 60
FIG. 33 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 61
FIG. 34 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million) 62
FIG. 35 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million) 65
FIG. 36 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 66
FIG. 37 Global API peptide therapeutics in-house market revenues, 2010 - 2018 (USD Million) 68
FIG. 38 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million) 69
FIG. 39 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million) 71
FIG. 40 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million) 72
FIG. 41 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million) 73
FIG. 42 Global peptide therapeutics market, by geography, 2011 - 2018 74
FIG. 43 North America peptide therapeutics market revenues, 2010 - 2018 (USD Million) 76
FIG. 44 Europe peptide therapeutics market revenues, 2010 - 2018 (USD Million) 77
FIG. 45 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 78
FIG. 46 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million) 79
FIG. 47 Global peptide therapeutics market share analysis of key players, 2011 (%) 81
FIG. 48 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%) 82
FIG. 49 Bachem Holding AG: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 87
FIG. 50 Eli Lilly & Company: annual revenues, 2009 – 2011 (USD Million) 89
FIG. 51 Pfizer, Inc.: annual revenues, 2009 – 2011 (USD Million) 91
FIG. 52 Amgen, Inc.: annual revenues, 2009 – 2011 (USD Million) 94
FIG. 53 Takeda Pharmaceutical Company Ltd.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 JPY = 0.01 USD) 97
FIG. 54 Teva Pharmaceuticals: annual revenues, 2009 – 2011 (USD Million) 99
FIG. 55 Lonza Inc.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 101
FIG. 56 Solvay Group: annual revenues, 2010 – 2011 (USD Million) (conversion rate: 1 Euro = 1.34 USD) 103
FIG. 57 Sanofi: annual revenues, 2009 – 2011 (USD Million) 105
FIG. 58 Ipsen: annual revenue Share, by geography, 2010 & 2011 (%) 107
FIG. 59 Ipsen: annual revenues, 2009 - 2011 (USD Million) 108
FIG. 60 Bristol-Myers Squibb: annual revenues, 2009 – 2011 (USD Million) 112
FIG. 61 AstraZaneca PLC: annual revenues, 2009 – 2011 (USD Million) 114
FIG. 62 Roche: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 116
FIG. 63 GSK: annual revenues, 2009 – 2011 (USD million) (conversion rate: 1 GBP = 1.5849 USD) 118
FIG. 64 Merck & Co.: annual revenues, 2009 – 2011 (USD Million) 120
FIG. 65 Novartis AG: annual revenues, 2009 – 2011 (USD Million) 123

List of Tables

TABLE 1 Global therapeutic peptides market: Snapshot 22
TABLE 2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million) 23
TABLE 3 Global scenario of acquisitions of biotech firms by large pharma giants 31
TABLE 4 Major peptide drugs and sales, 2011 (USD Million) 31
TABLE 5 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million) 36
TABLE 6 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million) 56
TABLE 7 Methods of delivery for peptide drugs 57
TABLE 8 Global peptide therapeutics market, revenues, by types 2010 - 2018 (USD million) 63
TABLE 9 Global API peptide therapeutics Market, By Revenue, by Types, 2010 - 2018 (USD million) 67
TABLE 10 Global peptide therapeutics market revenues, by technology, 2010 - 2018 (USD Million) 70
TABLE 11 Global Peptide Therapeutics Market, By Geography, 2010-2018 (USD Million) 75

Enquiry Before Buying


Free Market Analysis


Peptides are short chains of amino acid monomers linked by amide bonds and are distinguished from proteins on the basis of size. As a standard, molecules with less than 50 amino acids are considered as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and helps in treatment of diseases by acting on the cell membrane. 

The major factors boosting the growth of this market are rise in the number of cancer patients and metabolic diseases, coupled with technological developments in this sector, with the introduction of hybrid method for synthesis of the peptides. 

There has been a change in trend of route of administration. Though the parenteral route of administration is the most common, there are advances being made to deliver medicines through the oral route, which is considered to be the most preferred one due to better patient compliance. The pulmonary route is also being intensely worked upon and is presently in R&D. However, it is estimated that the parenteral method will continue to have the maximum share throughout the study period 

The CMOs (Contract Manufacturing Organizations) market for API peptide synthesis are expected to have a healthy growth since majority of the manufacturing companies are now considering outsourcing their peptide manufacturing, which would help them to focus on their own core competencies. 

The North American peptide therapeutics market holds the maximum market share followed by the European region. However, the market size of the North American region is anticipated to decline due to rise in the healthcare budget cuts and financial containment issues. Similarly, the European market is affected by the Euro crisis. Asia is the fastest growing region of the market owing to rise in disposable income and demand for better health services, propelling the growth of this market. 

The global peptide therapeutics market by major players includes companies like Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsen and others, while the CMOs market include major players like Bachem, Polypeptide Group, Lonza, Peptisyntha and others.

global-peptide-therapeutics-market-by-revenue-2010-2018
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research